Understanding the Class Action Lawsuit for ALT Investors
Attention investors in Altimmune, Inc. (NASDAQ: ALT)! If you have been affected by the recent developments affecting the company’s stock performance, it's crucial to review your legal rights in light of a class action securities lawsuit. Levi & Korsinsky, LLP is stepping forth to notify affected investors of their potential avenues for recovery.
Defining the Class
This lawsuit aims to provide reparations for investors who may have suffered losses attributed to alleged securities fraud during a defined period, which spans from August 10, 2023, to June 25, 2025. It’s essential for investors to stay informed about these occurrences, particularly if they had invested within this timeframe.
Details of the Case
On June 26, 2025, Altimmune published a press release disclosing topline results from its IMPACT Phase 2b MASH trial involving Pemvidutide. Unfortunately, the results did not meet the inflated expectations that had been set prior, revealing a failure to achieve statistical significance regarding the primary endpoint related to fibrosis reduction. Investors were left startled, especially when the news led to a sharp decline in stock price, falling from $7.71 to $3.61 per share in just one day, representing a staggering decrease of 53.2%.
Your Rights as an Investor
If you suffered financial losses due to these unsettling developments, it’s important to act swiftly. You have until October 6, 2025, to file a request for the court to appoint you as a lead plaintiff in this case. While serving as a lead plaintiff can be advantageous, it’s important to note that you can still receive compensation without taking this specific role.
No Costs Involved
For those concerned about the financial implications of participating in this lawsuit, rest assured that if you are a class member, you may be eligible for compensation without any out-of-pocket charges or obligations. This means that you can seek justice without incurring personal expenses.
Why Choose Levi & Korsinsky?
Levi & Korsinsky has a longstanding reputation for championing the rights of investors, with over 20 years of experience. Their dedicated team has secured significant settlements and verdicts for shareholders across numerous high-stakes cases. Having consistently ranked among the top securities litigation firms, they boast a team of over 70 skilled professionals ready to assist clients.
Contact Information
If you need assistance or wish to learn more about your rights as an investor, reach out to Joseph E. Levi, Esq. You can contact him via email at jlevi@levikorsinsky.com or by phone at (212) 363-7500. Additionally, you can visit their website for further information.
Frequently Asked Questions
1. What is the lawsuit about?
The lawsuit addresses potential securities fraud that may have caused significant financial losses to investors of Altimmune between August 2023 and June 2025.
2. How can I participate in the lawsuit?
You can file a request to be appointed as a lead plaintiff until October 6, 2025, or contact the law firm for further assistance.
3. Is it free to participate in the lawsuit?
Yes, if you're a class member, you may receive compensation without any associated costs or fees.
4. Who can I contact for more information?
You can reach out to Joseph E. Levi, Esq. at Levi & Korsinsky for detailed information.
5. What were the results of the MASH trial?
The trial failed to achieve the expected statistical significance concerning fibrosis reduction, impacting the company’s stock performance dramatically.
